Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cisplatin for small-cell lung cancer.

J Aisner1, J Abrams

  • 1Department of Medicine and Oncology, University of Maryland Cancer Center, Baltimore 21201.

Seminars in Oncology
|August 1, 1989
PubMed
Summary

Cisplatin and etoposide (EP) chemotherapy is effective for small-cell lung cancer (SCLC), especially with radiation. Aggressive combinations like EP show promise but require further study to manage toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of uterine atony in obstetric anaesthesia.

BJA education·2026
Same author

Aspiration risk assessment for postpartum tubal ligation using gastric ultrasound: a single-center prospective observational trial.

International journal of obstetric anesthesia·2026
Same author

Laryngo- rhino- otologie·2026
Same author

[Spontaneous course of traumatic tympanic membrane perforations].

HNO·2021
Same author

Impacts of Regulations on Air Quality and Emergency Department Visits in the Atlanta Metropolitan Area, 1999-2013.

Research report (Health Effects Institute)·2019
Same author

Relationship between remote cholecystectomy and incident Clostridioides difficile infection.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018

Area of Science:

  • Oncology
  • Medical Chemistry

Background:

  • Small-cell lung cancer (SCLC) is highly responsive to chemotherapy, with combination regimens forming the standard of care.
  • Established chemotherapeutic agents often show diminished efficacy after prior treatments.

Purpose of the Study:

  • To evaluate the efficacy of cisplatin-based chemotherapy in small-cell lung cancer, particularly in the context of minimal prior therapy.
  • To explore the synergistic potential of cisplatin with other agents, focusing on the EP (cisplatin, etoposide) combination.

Main Methods:

  • Review of existing data on antineoplastic activity of agents in SCLC.
  • Analysis of the efficacy of the EP combination as an initial, alternating, and salvage regimen.
  • Assessment of EP combined with chest irradiation for limited-stage SCLC.
  • Evaluation of aggressive regimens like CEP (high-dose EP, cyclophosphamide) and PACE (cisplatin, doxorubicin, cyclophosphamide, etoposide).

Main Results:

  • Cisplatin, though modestly active alone, is likely highly active in minimal prior therapy settings and its response may be dose-dependent.
  • The EP combination demonstrates significant synergy and consistent responses, even as a salvage regimen.
  • EP with concurrent chest irradiation yields results comparable to more aggressive approaches in limited disease SCLC.
  • CEP showed increased response frequency in extensive disease SCLC.
  • A pilot study of PACE was halted due to toxicity, but follow-up suggests potential survival benefits.

Conclusions:

  • The EP combination, with or without chest irradiation, represents a strong treatment option for SCLC, serving as a benchmark and foundation for more intensive strategies.
  • Aggressive chemotherapy combinations, potentially enhanced by colony-stimulating factors for toxicity management, warrant further investigation in SCLC treatment.

Related Experiment Videos